4.1 Review

Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSM

期刊

CURRENT HEMATOLOGIC MALIGNANCY REPORTS
卷 11, 期 6, 页码 456-461

出版社

CURRENT MEDICINE GROUP
DOI: 10.1007/s11899-016-0341-2

关键词

Social media; Twitter; Myeloproliferative neoplasm; Disease-specific hashtag; Myelofibrosis; Polycythemia vera

资金

  1. MD Anderson Cancer Center Support Grant [P30 CA016672]
  2. Healthcare Hashtags Project

向作者/读者索取更多资源

The social media platform Twitter has provided the hematology/oncology community with unprecedented, novel methods of interpersonal communication and increased ability for the dissemination of important updates in a rapidly moving field. The advent, and subsequent success, of disease-specific Twitter communities have further enabled interested healthcare stakeholders to become quickly organized around a unique set of rare medical conditions, such as hematologic malignancies, that, historically, generally lack large amounts of reliable online information. One example is the Twitter community #MPNSM (myeloproliferative neoplasms on social media), which was started approximately one and half years ago and has served as a recognized venue for discussion among many members of the MPN community, including patients, researchers, providers, and advocacy organizations. This article will focus on understanding the impact of the founding of this community via the analysis of advanced Twitter metrics of user experience, from the first year of use for this novel healthcare hashtag.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Oncology

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

Moshe Talpaz, Jean-Jacques Kiladjian

Summary: Myelofibrosis is a serious bone marrow disorder characterized by splenomegaly, and Fedratinib, a selective JAK2 inhibitor, has shown promising results in treating MF patients by targeting the JAK/STAT signaling pathway.

LEUKEMIA (2021)

Letter Gastroenterology & Hepatology

Benefits of molecular profiling with next-generation sequencing for the diagnosis and prognosis of myeloproliferative neoplasms in splanchnic vein thrombosis

Jean-Jacques Kiladjian, Pierre-Edouard Debureaux, Aurelie Plessier, Juliette Soret-Dulphy, Dominique Valla, Bruno Cassinat, Pierre-Emmanuel Rautou

JOURNAL OF HEPATOLOGY (2021)

Article Health Care Sciences & Services

Evaluating Scholars' Impact and Influence: Cross-sectional Study of the Correlation Between a Novel Social Media-Based Score and an Author-Level Citation Metric

Lucas Oliveira J. E. Silva, Graciela Maldonado, Tara Brigham, Aidan F. Mullan, Audun Utengen, Daniel Cabrera

Summary: This study revealed a weak positive correlation between a novel author-level complementary metric and the h-index, suggesting a bridge between the traditional citation metrics and novel social media-based metrics.

JOURNAL OF MEDICAL INTERNET RESEARCH (2021)

Article Hematology

Revisiting Diagnostic performances of serum erythropoietin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurement

Nabih Maslah, Odonchimeg Ravdan, Louis Drevon, Emmanuelle Verger, Celia Belkhodja, Christine Chomienne, Bruno Cassinat, Jean-Jacques Kiladjian, Stephane Giraudier, Marie-Helene Schlageter

Summary: This study evaluated the diagnostic performances of erythropoietin and JAK2 mutations in patients suspected of polycythemia, finding that low erythropoietin levels and JAK2 mutations have comparable positive predictive values for true polycythemia.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Article Cell Biology

Altered Ca2+ Homeostasis in Red Blood Cells of Polycythemia Vera Patients Following Disturbed Organelle Sorting during Terminal Erythropoiesis

Ralfs Buks, Tracy Dagher, Maria Giustina Rotordam, David Monedero Alonso, Sylvie Cochet, Emilie-Fleur Gautier, Philippe Chafey, Bruno Cassinat, Jean-Jacques Kiladjian, Nadine Becker, Isabelle Plo, Stephane Egee, Wassim El Nemer

Summary: The research reveals that there are elevated levels of multiple calcium binding proteins as well as endoplasmic-reticulum-residing proteins in the red blood cell membranes of patients with Polycythemia Vera (PV). Moreover, the study also indicates that the JAK2(V617F) mutation has an impact on calcium homeostasis and red blood cell ion channel activity.
Article Hematology

An inherited gain-of-function risk allele in EPOR predisposes to familial JAK2V617F myeloproliferative neoplasms

Graciela Rabadan Moraes, Florence Pasquier, Christophe Marzac, Eric Deconinck, Carlotta Caterina Damanti, Gwendoline Leroy, Mira El-Khoury, Wassim El Nemer, Jean-Jacques Kiladjian, Hana Raslova, Albert Najman, William Vainchenker, Caroline Marty, Christine Bellanne-Chantelot, Isabelle Plo

Summary: This study identified an EPOR variant in a large family with JAK2-positive MPN, indicating the importance of inherited-risk alleles affecting the JAK2/STAT pathway in MPN. The findings suggest potential implications for risk assessment and treatment of MPN.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Letter Oncology

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Jean-Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans C. Hasselbalch, Robert Kralovics, Heinz Gisslinger

LEUKEMIA (2022)

Article Oncology

Phase III MANIFEST-2: pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor treatment-naive myelofibrosis

Claire N. Harrison, Vikas K. Gupta, Aaron T. Gerds, Raajit Rampal, Srdan Verstovsek, Moshe Talpaz, Jean-Jacques Kiladjian, Ruben Mesa, Andrew T. Kuykendall, Alessandro M. Vannucchi, Francesca Palandri, Sebastian Grosicki, Timothy Devos, Eric Jourdan, Marielle J. Wondergem, Haifa Kathrin Al-Ali, Veronika Buxhofer-Ausch, Alberto Alvarez-Larran, Andrea Patriarca, Marina Kremyanskaya, Adam J. Mead, Sanjay Akhani, Yuri Sheikine, Gozde Colak, John Mascarenhas

Summary: Myelofibrosis (MF) is a rare type of blood cancer that leads to scarring in the bone marrow and a lack of healthy blood cell production. The current standard treatment, ruxolitinib, has limited efficacy in improving symptoms long term. Pelabresib is a new drug being developed for MF. This article describes the design of the ongoing MANIFEST-2 study, which is evaluating the effectiveness and safety of pelabresib and ruxolitinib compared to placebo and ruxolitinib in MF patients.

FUTURE ONCOLOGY (2022)

Article Oncology

Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis

Ruben Mesa, Claire Harrison, Stephen T. Oh, Aaron T. Gerds, Vikas Gupta, John Catalano, Francisco Cervantes, Timothy Devos, Marek Hus, Jean-Jacques Kiladjian, Ewa Lech-Maranda, Donal McLornan, Alessandro M. Vannucchi, Uwe Platzbecker, Mei Huang, Bryan Strouse, Barbara Klencke, Srdan Verstovsek

Summary: JAK inhibitors are effective for myelofibrosis, but do not address anemia. Momelotinib, targeting ACVR1/ALK2, JAK1 and JAK2, shows activity against anemia, symptoms, and splenomegaly.

LEUKEMIA (2022)

Review Oncology

Biological drivers of clinical phenotype in myelofibrosis

John Mascarenhas, Helene F. E. Gleitz, Helen T. Chifotides, Claire N. Harrison, Srdan Verstovsek, Alessandro Maria Vannucchi, Raajit K. Rampal, Jean-Jacques Kiladjian, William Vainchenker, Ronald Hoffman, Rebekka K. Schneider, Alan F. List

Summary: Myelofibrosis is a myeloproliferative disorder with significant biological and clinical heterogeneity. It can manifest as a cytopenic phenotype or a myeloproliferative phenotype, each with different prognosis and response to treatment. Patients with the cytopenic phenotype have worse outcomes and pose challenges in treatment. Recent data suggest that an innate immune deregulated state may be associated with the cytopenic phenotype, providing potential for novel treatment approaches.

LEUKEMIA (2022)

Review Hematology

Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies

Jean-Jacques Kiladjian, Bruno Cassinat

Summary: Myeloproliferative neoplasms (MPNs) are a common cause of primary splanchnic vein thrombosis, present in about 40% of patients. Diagnosis can be challenging due to confounding factors like portal hypertension or bleeding complications. However, improved diagnostic tools, including molecular markers, have helped in accurate diagnosis and prognosis estimation. A multidisciplinary approach is crucial to determine the subtype and recommend appropriate tests and treatment strategies for patients with splanchnic vein thrombosis and MPNs.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Review Oncology

Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape

Nabih Maslah, Lina Benajiba, Stephane Giraudier, Jean-Jacques Kiladjian, Bruno Cassinat

Summary: Myeloproliferative neoplasms are characterized by driver mutations targeting the JAK/STAT pathway and often display additional mutations targeting various pathways. The disease progression typically involves a chronic phase followed by an accelerated phase or transformation into more aggressive diseases. Recent studies have shed light on the rates and mechanisms of mutation acquisition and selection in hematopoietic cells, using novel techniques to decipher clonal architecture and mutation-induced cell modifications at the single cell level.

LEUKEMIA (2023)

Article Hematology

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis

Vikas Gupta, John Mascarenhas, Marina Kremyanskaya, Raajit K. Rampal, Moshe Talpaz, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Srdan Verstovsek, Gozde Colak, Debarshi Dey, Claire Harrison

Summary: A study suggests that pelabresib in combination with ruxolitinib may have higher efficacy in treating JAKi treatment-naive MF patients compared to JAKi monotherapy, with significant improvements in spleen volume reduction and total symptom scores.

BLOOD ADVANCES (2023)

Article Hematology

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3 active-comparator, controlled trial

Regis Peffault de Latour, Jeff Szer, Ilene C. Weitz, Alexander Roth, Britta Hochsmann, Jens Panse, Kensuke Usuki, Morag Griffin, Jean-Jacques Kiladjian, Carlos M. de Castro, Hisakazu Nishimori, Temitayo Ajayi, Mohammed Al-Adhami, Pascal Deschatelets, Cedric Francois, Federico Grossi, Antonio M. Risitano, Peter Hillmen

Summary: The PEGASUS trial demonstrated the long-term efficacy and safety of pegcetacoplan in improving outcomes for patients with paroxysmal nocturnal haemoglobinuria. Both treatment groups showed significant improvements in haemoglobin concentration and quality of life, indicating the potential of pegcetacoplan as a therapeutic option.

LANCET HAEMATOLOGY (2022)

Article Hematology

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition

Nabih Maslah, Emmanuelle Verger, Stephane Giraudier, Mathias Chea, Ronald Hoffman, John Mascarenhas, Bruno Cassiant, Jean-Jacques Kiladjian

Summary: This study demonstrates the direct effect of MDM2 inhibition on the selection of MPN patients' cells harboring TP53 mutations. TP53 mutations are late events in MPN, mainly occurring in the driver clone, and clonal evolution frequently consists of sequential branching instead of linear consecutive acquisition of mutations in the same clone.

BLOOD ADVANCES (2022)

暂无数据